<DOC>
	<DOCNO>NCT01686555</DOCNO>
	<brief_summary>To assess safety , tolerability pharmacokinetics ABT-199 female subject Systemic Lupus Erythematosus .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Pharmacokinetics ABT-199 Female Patients With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description>This phase 1 , randomize , double-blind , placebo-controlled , single-and multiple ascend dose study . Up eighty-eight subject Systemic Lupus Erythematosus select participate . Subjects randomize receive either ABT-199 placebo . Subjects administer ABT-199/placebo single dose 14 day multiple dos .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Diagnosis systemic lupus erythematosus least 6 month . Documentation least one following : ANA titer &gt; = 1:160 positive antidsDNA antibody . Stable systemic lupus erythematosus medication regimen . Other systemic lupus erythematosus , subject general good health . Male . Druginduced highly active systemic lupus erythematosus . Significant autoimmune disease lupus . Significant , uncontrolled unstable disease organ .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>